Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies

Background and Objectives. The incidence of invasive filamentous fungal infections in hematologic patients is increasing as a consequence of high dose chemotherapy and bone marrow transplant procedures. Mortality is usually very high. The diagnosis is often difficult and yet a fast, accurate diagnosis is of fundamental importance for treating the infection and planning subsequent management of the hematologic disease. We evaluated the sensitivity of computed tomography (CT)-guided percutaneous biopsy in diagnosing pulmonary fungal infections. Design and Methods. Between 1997 and 2002 we performed 17 CT-guided percutaneous transthoracic lung biopsies in 17 hematologic patients with suspected filamentous fungi infection with negative BAL, to obtain a certain diagnosis and to know what species of fungi was responsible for infection. In all cases suspected mycosis began during the post-chemotherapy aplastic period. Patients were receiving antifungal therapy at the time of all biopsies. When the platelet count rose above 50 7109/L, CT-guided percutaneous lung biopsy with fine-needle aspiration for cytology was performed. Results. Twelve of 17 patients had histologic confirmation of the fungal infection (70.5%), 8 with Aspergillus spp. 4 with Mucorales spp. Biopsies provided non-specific results in 4 cases; in 2 of these cases, clinical course and response to therapy confirmed the diagnosis of mycosis; in the last case bronchoalveolar carcinoma was found as a new diagnosis. Cultures were positive in only 6 cases, all for Aspergillus spp. The sensitivity of CT-guided percutaneous lung biopsy was 70.6% and its positive predictive value (PPV) was 100%. This procedure provided an immediate diagnosis and only one side-effect (1 pneumothorax, without complications). Interpretation and Conclusions. Histologic discrimination between aspergillosis and mucormycosis is very important for deciding secondary prophylaxis during transplant procedures, because Mucor is usually resistant to azoles

Assessing energy expenditure in cancer patients: a pilot validation of a new wearable device.

BACKGROUND: Nutrition problems are common in cancer patients and are frequently due to metabolic derangements. Thus, accurately assessing energy expenditure (EE) is important in planning adequate nutrition support. Indirect calorimetry (IC) represents the gold standard method but is not always available or applicable to all settings. The purpose of this study was to preliminary compare a new wearable device, the SenseWear armband (SWA), to IC in cancer patients.METHODS: Ten (6 M, 4 F) subjects (mean +/- SD: 56.6 +/- 13.3 years) affected by newly diagnosed acute myelogenous leukemia, undergoing induction chemotherapy, were prospectively enrolled. Resting EE (REE) was measured simultaneously by SWA and IC on admission (day 0) and at discharge (end). Total daily EE (TDEE) was determined by SWA 4 times during the stay (days 0, 7, 14, and end) and predicted values were calculated according to IC REE estimates (TDEE = IC x correction factor 1.2). RESULTS: Mean length of stay was 27.1 +/- 6.2 days. Bland-Altman plots revealed no significant differences between overall REE estimates (day 0 + end) performed by IC and SWA (mean +/- SD; 1645 +/- 282 vs 1705 +/- 278 kcal/d) and the correlation was high (r = 0.84; p < .0001). SWA TDEE showed a progressive reduction during the stay. No bias was detected between overall SWA TDEE (1799 +/- 153 kcal/d) and IC predicted TDEE (1974 +/- 176 kcal/d), but there was a wide 95% confidence interval (-672; +321 kcal/d). Moreover, the correlation between these values was significant (r = 0.68; p = .001). CONCLUSIONS: SWA seems to provide accurate and reliable estimation of REE and useful information on TDEE also in cancer patients. Its use appears promising. Validation studies on larger samples and different cancer types should be considered

CA-125 in benign and malignant diseases involving coelomic epithelium

The presence of CA-125 (cut-off 35 U/ml) was assessed in serum from 263 neoplastic and 65 non neoplastic patients and in the pleural or ascitic fluid from 84 of them (49 neoplastic and 35 non neoplastic). Tumors (including mesotheliomas, mucinous and non-mucinous ovarian carcinomas, primitive and metastatic cancers of lung and liver and of the digestive tract) were staged according to TNM and FIGO classification and the tumors with peritoneal or pleural effusion considered apart. Non malignant patients had liver cirrhosis, lung inflammation and effusions due to heart failure. CA-125 was positive in most of the sera from patients with ovarian cancer and benign and malignant serous involvement; high concentrations were found in all examined effusions. The relationship between development of serous effusion and the increasing level of serum CA-125 could explain the abnormal serum concentrations found in diseases with peritoneal or pleural involvement. This could also explain the increased levels of CA-125 and ovarian carcinoma (including mucinous) progression which may extend resulting in peritoneal localization. Elevation of serum CA-125 may be expected in patients with all types of diseases affecting peritoneum and pleura and this marker may be used in the follow-up of epithelial ovarian carcinomas as well as of tumors involving coelomic epithelium